Global Drug Eluting Stents (DES) Drug Pipeline Market Report 2022: Stages of Development, Regulatory Path, Estimated Approval Date, Ongoing Clinical Trials, Key Companies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--Sep 15, 2022--

The "Drug Eluting Stents (DES) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

The report provides comprehensive information about the Drug Eluting Stents (DES) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Drug eluting stents (DES) release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery.

Scope

• Extensive coverage of the Drug Eluting Stents (DES) under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Drug Eluting Stents (DES) Overview

3 Products under Development

3.1 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development

3.2 Drug Eluting Stents (DES) - Pipeline Products by Territory

3.3 Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path

3.4 Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date

3.5 Drug Eluting Stents (DES) - Ongoing Clinical Trials

4 Drug Eluting Stents (DES) - Pipeline Products under Development by Companies

4.1 Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development

4.2 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development

5 Drug Eluting Stents (DES) Companies and Product Overview

5.1 Abbott Vascular Inc Company Overview

5.2 Adcomp Technologies Inc. Company Overview

5.3 Advanced Bifurcation Systems Inc Company Overview

5.4 Aeon Bioscience Company Overview

5.5 B. Braun Melsungen AG Company Overview

5.6 Biosensors International Group Ltd Company Overview

5.7 Biotronik AG Company Overview

5.8 Biotronik SE & Co KG Company Overview

5.9 Boston Scientific Corp Company Overview

5.10 Cardionovum GmbH Company Overview

5.11 Cardiorev Pte Ltd (Inactive) Company Overview

5.12 Columbia University Company Overview

5.13 Concept Medical Inc Company Overview

5.14 Cordis Corp Company Overview

5.15 DISA Vascular (Pty) Ltd Company Overview

5.16 Elixir Medical Corp Company Overview

5.17 Envision Scientific Pvt Ltd Company Overview

5.18 I.B.S. S.p.A. Company Overview

5.19 InspireMD Inc Company Overview

5.20 JW Medical Systems Ltd Company Overview

5.21 Kaneka Corp Company Overview

5.22 MangoGen Pharma Inc Company Overview

5.23 Medinol Ltd Company Overview

5.24 Medlogics Device Corp (Inactive) Company Overview

5.25 Medtronic Plc Company Overview

5.26 MicroPort Scientific Corp Company Overview

5.27 MIV Therapeutics Inc Company Overview

5.28 NuVascular Technologies Inc Company Overview

5.29 Relisys Medical Devices Ltd Company Overview

5.30 REVA Medical Inc Company Overview

5.31 Sahajanand Medical Technologies Pvt Ltd Company Overview

5.32 Shanghai BIOMAGIC Medical Device Co Ltd Company Overview

5.33 Shanghai MicroPort Medical Group Co Ltd Company Overview

5.34 Sino Medical Sciences Technology Inc Company Overview

5.35 Stentys SA Company Overview

5.36 Svelte Medical Systems Inc Company Overview

5.37 Terumo Corp Company Overview

5.38 Terumo Interventional Systems Company Overview

5.39 TissueGen Inc Company Overview

5.40 Translumina Therapeutics LLP Company Overview

5.41 University of Strathclyde Company Overview

5.42 VasoTech Inc. Company Overview

6 Drug Eluting Stents (DES)- Recent Developments

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/kdaiuu

View source version on businesswire.com:https://www.businesswire.com/news/home/20220915005867/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2022.